Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration.
The Gelrin hydrogel platform is a matrix of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen, combining the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications.
The company’s flagship product, GelrinC, for the treatment of articular cartilage lesions, is currently in clinical trials.
|
